Serum matrix metalloproteinases in adult CF patients: Relation to pulmonary exacerbation

Journal of Cystic Fibrosis

Volumn 8, Issue 5, 2009, Pages 338-347

  Roderfeld, Martin ^a   Rath, Timo ^a   Schulz, Richard ^a   Seeger, Werner ^a   Tschuschner, Annette ^a   Graf, Jürgen ^b   Roeb, Elke ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Cystic fibrosis; Inflammation; Lung; Matrix metalloproteinases; Tissue inhibitors of metalloproteinases

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOPENICILLIN; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; COLLAGENASE 3; GELATINASE A; GELATINASE B; GYRASE INHIBITOR; INTERSTITIAL COLLAGENASE; MACROLIDE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; NEUTROPHIL COLLAGENASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE EXACERBATION; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; SCORING SYSTEM;

ADULT; BIOLOGICAL MARKERS; CYSTIC FIBROSIS; HEALTH STATUS; HEALTH STATUS INDICATORS; HUMANS; MALE; MATRIX METALLOPROTEINASES; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX;

EID: 69549105799     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2009.06.001     Document Type: Article

References (39)

1. Genetic testing for cystic fibrosis. NIH Consens Statement 15 (1997) 1-37
2. Accurso F.J. Update in cystic fibrosis 2007. Am J Respir Crit Care Med 177 (2008) 1058-1061
3. Boyle M.P. Adult cystic fibrosis. JAMA 298 (2007) 1787-1793
4. Ferkol T., Rosenfeld M., and Milla C.E. Cystic fibrosis pulmonary exacerbations. J Pediatr 148 (2006) 259-264
5. Clinical practice guidelines for cystic fibrosis (1997), Cystic Fibrosis Foundation, Bethesda, MD
6. Ramsey B.W., and Boat T.F. Outcome measures for clinical trials in cystic fibrosis. Summary of a Cystic Fibrosis Foundation consensus conference. J Pediatr 124 (1994) 177-192
7. Sagel S.D., Kapsner R.K., and Osberg I. Induced sputum matrix metalloproteinase-9 correlates with lung function and airway inflammation in children with cystic fibrosis. Pediatr Pulmonol 39 (2005) 224-232
8. Elkington P.T., and Friedland J.S. Matrix metalloproteinases in destructive pulmonary pathology. Thorax 61 (2006) 259-266
9. Gueders M.M., Foidart J.M., Noel A., and Cataldo D.D. Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: potential implications in asthma and other lung diseases. Eur J Pharmacol 533 (2006) 133-144
10. Parks W.C., and Shapiro S.D. Matrix metalloproteinases in lung biology. Respir Res 2 (2001) 10-19
11. Gaggar A., Li Y., Weathington N., Winkler M., Kong M., Jackson P., et al. Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patients. Am J Physiol Lung Cell Mol Physiol 293 (2007) L96-L104
12. Hilliard T.N., Regamey N., Shute J.K., Nicholson A.G., Alton E.W., Bush A., et al. Airway remodelling in children with cystic fibrosis. Thorax 62 (2007) 1074-1080
13. Ratjen F., Hartog C.M., Paul K., Wermelt J., and Braun J. Matrix metalloproteases in BAL fluid of patients with cystic fibrosis and their modulation by treatment with dornase alpha. Thorax 57 (2002) 930-934
14. Flume P.A., O'Sullivan B.P., Robinson K.A., Goss C.H., Mogayzel Jr. P.J., Willey-Courand D.B., et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 176 (2007) 957-969
15. Kerem E., Conway S., Elborn S., and Heijerman H. Standards of care for patients with cystic fibrosis: a European consensus. J Cyst Fibros 4 (2005) 7-26
16. Miller M.R., Hankinson J., Brusasco V., Burgos F., Casaburi R., Coates A., et al. Standardisation of spirometry. Eur Respir J 26 (2005) 319-338
17. Rosenfeld M., Emerson J., Williams-Warren J., Pepe M., Smith A., Montgomery A.B., et al. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 139 (2001) 359-365
18. Meisner M., Tschaikowsky K., Palmaers T., and Schmidt J. Comparison of procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS. Crit Care 3 (1999) 45-50
19. Gibson R.L., Burns J.L., and Ramsey B.W. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 168 (2003) 918-951
20. Rosenfeld M., Gibson R.L., McNamara S., Emerson J., Burns J.L., Castile R., et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol 32 (2001) 356-366
21. Aaron S.D., Ramotar K., Ferris W., Vandemheen K., Saginur R., Tullis E., et al. Adult cystic fibrosis exacerbations and new strains of Pseudomonas aeruginosa. Am J Respir Crit Care Med 169 (2004) 811-815
22. Dakin C., Henry R.L., Field P., and Morton J. Defining an exacerbation of pulmonary disease in cystic fibrosis. Pediatr Pulmonol 31 (2001) 436-442
23. Rabin H.R., Butler S.M., Wohl M.E., Geller D.E., Colin A.A., Schidlow D.V., et al. Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 37 (2004) 400-406
24. Higashimoto Y., Iwata T., Okada M., Satoh H., Fukuda K., and Tohda Y. Serum biomarkers as predictors of lung function decline in chronic obstructive pulmonary disease. Resp Med 103 (2009) 1231-1238
25. Brajer B., Batura-Gabryel H., Nowicka A., Kuznar-Kaminska B., and Szczepanik A. Concentration of matrix metalloproteinase-9 in serum of patients with chronic obstructive pulmonary disease and a degree of airway obstruction and disease progression. J Physiol Pharmacol 59 Suppl 6 (2008) 145-152
26. Perez A., van Heeckeren A.M., Nichols D., Gupta S., Eastman J.F., and Davis P.B. Peroxisome proliferator-activated receptor-gamma in cystic fibrosis lung epithelium. Am J Physiol Lung Cell Mol Physiol 295 (2008) 303-313
27. Gaggar A., Jackson P.L., Noerager B.D., O'Reilly P.J., McQuaid D.B., Rowe S.M., et al. A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation. J Immunol 180 (2008) 5662-5669
28. Cataldo D.D., Gueders M.M., Rocks N., Sounni N.E., Evrard B., Bartsch P., et al. Pathogenic role of matrix metalloproteases and their inhibitors in asthma and chronic obstructive pulmonary disease and therapeutic relevance of matrix metalloproteases inhibitors. Cell Mol Biol (Noisy-le-grand) 49 (2003) 875-884
29. Elshaw S.R., Henderson N., Knox A.J., Watson S.A., Buttle D.J., and Johnson S.R. Matrix metalloproteinase expression and activity in human airway smooth muscle cells. Br J Pharmacol 142 (2004) 1318-1324
30. Xu J., Benyon R.C., Leir S.H., Zhang S., Holgate S.T., and Lackie P.M. Matrix metalloproteinase-2 from bronchial epithelial cells induces the proliferation of subepithelial fibroblasts. Clin Exp Allergy 32 (2002) 881-888
31. Roeb E., Graeve L., Hoffmann R., Decker K., Edwards D.R., and Heinrich P.C. Regulation of tissue inhibitor of metalloproteinases-1 gene expression by cytokines and dexamethasone in rat hepatocyte primary cultures. Hepatology 18 (1993) 1437-1442
32. D'Armiento J., Dalal S.S., Okada Y., Berg R.A., and Chada K. Collagenase expression in the lungs of transgenic mice causes pulmonary emphysema. Cell 71 (1992) 955-961
33. Dunsmore S.E., Saarialho-Kere U.K., Roby J.D., Wilson C.L., Matrisian L.M., Welgus H.G., et al. Matrilysin expression and function in airway epithelium. J Clin Invest 102 (1998) 1321-1331
34. Fligiel S.E., Standiford T., Fligiel H.M., Tashkin D., Strieter R.M., Warner R.L., et al. Matrix metalloproteinases and matrix metalloproteinase inhibitors in acute lung injury. Hum Pathol 37 (2006) 422-430
35. Segura-Valdez L., Pardo A., Gaxiola M., Uhal B.D., Becerril C., and Selman M. Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest 117 (2000) 684-694
36. Chakrabarti S., and Patel K.D. Matrix metalloproteinase-2 (MMP-2) and MMP-9 in pulmonary pathology. Exp Lung Res 31 (2005) 599-621
37. McQuibban G.A., Gong J.H., Wong J.P., Wallace J.L., Clark-Lewis I., and Overall C.M. Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood 100 (2002) 1160-1167
38. Huhtala P., Tuuttila A., Chow L.T., Lohi J., Keski-Oja J., and Tryggvason K. Complete structure of the human gene for 92-kDa type IV collagenase. Divergent regulation of expression for the 92- and 72-kilodalton enzyme genes in HT-1080 cells. J Biol Chem 266 (1991) 16485-16490
39. Templeton N.S., and Stetler-Stevenson W.G. Identification of a basal promoter for the human Mr 72000 type IV collagenase gene and enhanced expression in a highly metastatic cell line. Cancer Res 51 (1991) 6190-6193